NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of “Moderate Buy” by Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $20.20.

Several brokerages recently issued reports on NEO. The Goldman Sachs Group lowered their price target on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a research report on Friday, January 10th. Bank of America raised their target price on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Jefferies Financial Group began coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective for the company.

Insider Buying and Selling

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares of the company’s stock, valued at $570,301.44. The trade was a 12.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank bought a new stake in NeoGenomics during the 4th quarter worth about $6,273,000. Loomis Sayles & Co. L P lifted its position in shares of NeoGenomics by 48.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,791,792 shares of the medical research company’s stock worth $29,528,000 after purchasing an additional 584,502 shares in the last quarter. Segall Bryant & Hamill LLC lifted its position in shares of NeoGenomics by 11.6% during the fourth quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company’s stock worth $34,836,000 after purchasing an additional 220,415 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of NeoGenomics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company’s stock valued at $234,673,000 after purchasing an additional 195,793 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of NeoGenomics in the fourth quarter valued at approximately $453,000. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Stock Performance

NASDAQ:NEO opened at $13.78 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. The firm’s 50-day moving average is $15.91 and its 200-day moving average is $15.64. NeoGenomics has a 52-week low of $12.13 and a 52-week high of $19.11. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -22.59 and a beta of 1.23.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.